synapse defective Rho GTPase activating protein 1Genealiases: 7h3 · SYD1
Q-omics provides the consensus-scored SYDE1 profile across patient tissues and cancer cell-line models. SYDE1 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, SYDE1 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, SYDE1 protein abundance shows 31,814 significant protein co-abundance associations, with the highest sampling consensus in CCRCC. Together, these results highlight BLCA, HNSC, and CCRCC as cancer lineages where SYDE1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SYDE1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SYDE1 survival associations across molecular data types. SYDE1 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (4) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SYDE1 RNA expression–survival associations across cancer types. High SYDE1 expression shows unfavorable associations in BLCA, MESO, OV, ACC, LGG and SKCM. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify BLCA as the clearest survival context for SYDE1 RNA expression.
This table summarizes SYDE1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 7. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for SYDE1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SYDE1 shows lower tumor expression in KICH, THCA, LUAD and UCEC and higher tumor expression in HNSC and KIRC. The HNSC box plot shows higher SYDE1 RNA expression in tumor versus normal tissue (log2 FC = +1.231, t-test p < 0.001).
This table shows molecular features associated with SYDE1 in patient tissues and cancer cell lines. In patient samples, SYDE1 shows the broadest associations at the RNA and protein expression levels, with CCRCC recurring as the lineage with the largest associated feature set. In cancer cell lines, SYDE1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and CNS.
